Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.11M | 0.00 | 65.97M | 80.91M | 91.96M |
Gross Profit | 2.11M | -10.50M | 65.97M | 80.91M | 91.96M |
EBITDA | -1.02B | -1.01B | -1.79B | -1.73B | -1.21B |
Net Income | -1.02B | -1.02B | -1.65B | -1.68B | -1.19B |
Balance Sheet | |||||
Total Assets | 3.19B | 3.55B | 4.58B | 4.95B | 6.12B |
Cash, Cash Equivalents and Short-Term Investments | 3.04B | 3.40B | 4.33B | 4.70B | 5.84B |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 142.21M | 155.81M | 199.30M | 260.53M | 116.96M |
Stockholders Equity | 3.04B | 3.39B | 4.38B | 4.69B | 6.00B |
Cash Flow | |||||
Free Cash Flow | -1.03B | -955.48M | -1.73B | -1.51B | -1.15B |
Operating Cash Flow | -999.00M | -932.76M | -1.71B | -1.50B | -1.15B |
Investing Cash Flow | 67.18M | 177.27M | 276.35M | 689.56M | -1.70B |
Financing Cash Flow | 667.26M | 27.65M | 1.33B | 354.72M | 4.99B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | ¥2.84T | 34.60 | 5.46% | 4.69% | 14.29% | 368.64% | |
74 Outperform | $3.93T | 9.78 | 15.51% | 1.74% | 10.17% | 226.18% | |
67 Neutral | ¥1.20T | 25.96 | 5.34% | 3.76% | 6.42% | 10.82% | |
67 Neutral | $6.68T | 48.36 | 1.99% | 4.65% | 1.52% | -8.68% | |
65 Neutral | ¥352.42B | 10.85 | -2.99% | 2.46% | 11.67% | -10.31% | |
56 Neutral | $26.12B | ― | -193.61% | ― | 179.79% | -204.13% | |
37 Underperform | ¥4.42B | ― | ― | -96.64% | 8.92% |
Ribomic Inc. has reported its non-consolidated financial results for the nine months ending December 31, 2024, showing a reduction in losses compared to the same period the previous year. The company maintains a strong equity ratio of over 95% and continues to forecast a stable financial outlook for the full year, despite no expected changes in dividends.